000 02401 a2200685 4500
005 20250516102603.0
264 0 _c20130523
008 201305s 0 0 eng d
022 _a1471-2407
024 7 _a10.1186/1471-2407-12-292
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aMekenkamp, Leonie J M
245 0 0 _aBeyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients.
_h[electronic resource]
260 _bBMC cancer
_cJul 2012
300 _a292 p.
_bdigital
500 _aPublication Type: Journal Article
650 0 4 _aAntibodies, Monoclonal
_xadministration & dosage
650 0 4 _aAntibodies, Monoclonal, Humanized
_xadministration & dosage
650 0 4 _aAntineoplastic Combined Chemotherapy Protocols
_xtherapeutic use
650 0 4 _aBevacizumab
650 0 4 _aCetuximab
650 0 4 _aChromosomes, Human, Pair 12
_xgenetics
650 0 4 _aClinical Trials, Phase III as Topic
650 0 4 _aColorectal Neoplasms
_xdrug therapy
650 0 4 _aDNA Copy Number Variations
650 0 4 _aDisease-Free Survival
650 0 4 _aFemale
650 0 4 _aHumans
650 0 4 _aMale
650 0 4 _aMicroRNAs
_xgenetics
650 0 4 _aMiddle Aged
650 0 4 _aMulticenter Studies as Topic
650 0 4 _aMultivariate Analysis
650 0 4 _aMutation
650 0 4 _aNeoplasm Metastasis
650 0 4 _aOrganoplatinum Compounds
_xadministration & dosage
650 0 4 _aOxaliplatin
650 0 4 _aProto-Oncogene Proteins
_xgenetics
650 0 4 _aProto-Oncogene Proteins p21(ras)
650 0 4 _aRandomized Controlled Trials as Topic
650 0 4 _aReverse Transcriptase Polymerase Chain Reaction
650 0 4 _aTreatment Outcome
650 0 4 _aras Proteins
_xgenetics
700 1 _aTol, Jolien
700 1 _aDijkstra, Jeroen R
700 1 _ade Krijger, Inge
700 1 _aVink-Börger, M Elisa
700 1 _avan Vliet, Shannon
700 1 _aTeerenstra, Steven
700 1 _aKamping, Eveline
700 1 _aVerwiel, Eugène
700 1 _aKoopman, Miriam
700 1 _aMeijer, Gerrit A
700 1 _avan Krieken, J Han Jm
700 1 _aKuiper, Roland
700 1 _aPunt, Cornelis J A
700 1 _aNagtegaal, Iris D
773 0 _tBMC cancer
_gvol. 12
_gp. 292
856 4 0 _uhttps://doi.org/10.1186/1471-2407-12-292
_zAvailable from publisher's website
999 _c21951633
_d21951633